Ondansetron Case Study Conclusion

7082 Words29 Pages
INTRODUCTION The most common post operative complications are pain and post operative nausea and vomiting. Post operative nausea and vomiting is challenging task for both surgeon and anesthesiologist due to adverse effects caused by it and delay in discharging the patient. The incidence of post operative nausea and vomiting is more following general anaesthesia than regional anaesthesia. Though there are multiple advances over several years in minimizing the adverse outcomes after anesthesia, patients continue to rank nausea and vomiting as their most undesirable outcome along with post operative pain. As an anesthetist we play vital role in controlling post operative nausea and vomiting. Apfel CC has said that post operative nausea and vomiting…show more content…
The use of palonosetron in pregnant women is not fully established though there are animal studies which show that there is no interference with fetal development and it is assigned as Category – B14. Similarly there is no much evidence for safe use of palonosetron in lactating mothers8. The side effects of the drug are headache, abdominal discomfort and dizziness. PHARMACOLOGY OF ONDANSETRON24, 25, 26 It is a selective 5HT3 receptor antagonist. Ondansetron was the first 5HT3 drug to be used for management of both CINV and PONV. Ondansetron was introduced in the year 1991 for management of nausea and vomiting. It is a carbazalone derivative. The molecular formula for ondansetron is C18H19N3O•HCl•2H2O. The molecular weight of ondansetron is 365.9. The chemical formula for ondansetron is (±) 1, 2, 3, 9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl) methyl]-4H-carbazol-4-one, mono hydrochloride, dehydrate. The structure of ondansetron is shown in figure 2. Ondansetron is available in both oral and parental preparation. Ondansetron undergoes first pass metabolism. Oral bioavailability of ondansetron is 60 – 70
Show More
Related

  • Oral Dispersible Tablets Case Study

    841 Words  | 4 Pages

    are an innovative technology, which disperse rapidly without the need for water, providing optimal convenience to the patient. Ondansetron is a selective 5-hydroxytryptamine type3 receptor antagonist used to treat chemotherapy and radiotherapy induced nausea and emesis. The aim of this study was to formulate effective taste-masked orally dispersible tablets of Ondansetron hydrochloride to get rapid onset of action, to increase bioavailability and to increase patient compliance. The bitter taste of

    Read More

More about Ondansetron Case Study Conclusion

Open Document